EC
FULC icon

EntryPoint Capital’s Fulcrum Therapeutics FULC Stock Holding History

EntryPoint Capital’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$347K Buy
45,248
+30,172
+200% +$280K 0.1% 405
2025
Q4 		$171K Buy
+15,076
New +$153K 0.07% 576

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

EntryPoint Capital's FULC Position: Q1 2026 in Review

EntryPoint Capital increased its Fulcrum Therapeutics (FULC) stake by 200% in Q1 2026, buying an estimated $280K and bringing the position to 45,248 shares worth $347K. The position accounts for 0.1% of the portfolio, ranked #405.

EntryPoint Capital first reported a position in FULC in Q4 2025 and has held it in 2 quarters since. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • EntryPoint Capital held 45,248 shares of Fulcrum Therapeutics worth $347K as of Q1 2026.
  • EntryPoint Capital bought 30,172 Fulcrum Therapeutics shares in Q1 2026, an estimated $280K.
  • Fulcrum Therapeutics made up 0.1% of EntryPoint Capital's portfolio in Q1 2026, its #405 holding.
  • EntryPoint Capital first reported a position in Fulcrum Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.